Importance

Loading Importance Indicators...

Abstract

Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent, said agent(s) having at least one amino acid residue, or a pharmacologically acceptable salt or derivative thereof (such as methotrexate or cyclosporin) in the treatment of conditions involving acutely or chronically inadequate immune response. Specific conditions that may be treated include chronic inflammatory diseases (e.g. Crohn's disease and ulcerative colitis) and tumour diseases (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased.

Loading the Abstract Image...

First Claim